STERIS /$STE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About STERIS

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Ticker

$STE
Sector

Primary listing

NYSE

Employees

17,787

STERIS Metrics

BasicAdvanced
$24B
37.95
$6.53
0.95
$2.28
0.92%

What the Analysts think about STERIS

Analyst ratings (Buy, Hold, Sell) for STERIS stock.

Bulls say / Bears say

Management raised reported revenue guidance for fiscal 2026 to 8–9%, up from the previous 6–7%, showing confidence in demand and pricing power underpinned by a favorable currency environment (Globe Newswire).
Free cash flow jumped 27% to $787.2 million in fiscal 2025 from $620.3 million a year prior, supported by better working capital management and higher collections, boosting the balance sheet (SEC 10-K).
Fiscal 2025 gross profit margin increased to 44.0% from 43.2% in FY 2024, benefiting from pricing, favorable mix, and productivity gains (SEC 10-K).
Steris expects a roughly $45 million negative pre-tax profit impact from new tariffs in fiscal 2026, which could limit margin expansion even as revenue rises (Globe Newswire).
The company booked a $48.15 million charge in fiscal 2025 to settle ethylene oxide emissions claims, pointing to persistent legal and environmental risks (Crain’s Cleveland Business).
Cash and cash equivalents fell to $171.7 million as of March 31, 2025 from $207.0 million at the end of fiscal 2024, weakening liquidity amid heavy capital spending and debt repayments (SEC 10-K).
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2025.

STERIS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

STERIS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept26
STERIS
DividendPayment
$0.63Per share
FAQs